Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenapanor

- PMLiVE

AstraZeneca study reveals increasing number of people impacted by chronic kidney disease

CKD is a progressive condition that affects nearly 850 million people worldwide

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

Novo Nordisk to buy KBP’s hypertension drug ocedurenone for up to $1.3bn

An estimated 1.28 billion adults aged 30 to 79 years worldwide have hypertension

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

- PMLiVE

Vironix and Oxford University partner to advance chronic kidney disease monitoring

The partners will aim to develop learning models that predict the progression of CKD

- PMLiVE

Eli Lilly and Boehringer’s Jardiance granted EC approval to treat chronic kidney disease

Approximately 47 million people in the EU are affected by the long-term kidney condition

- PMLiVE

FDA advisory committee recommends Ardelyx’s Xphozah for chronic kidney disease

The phase 3 trials supporting the submission met all primary and key secondary endpoints

- PMLiVE

Boehringer and Lilly’s Jardiance shows promise in phase 3 chronic kidney disease trial

Jardiance reduced disease progression and cardiovascular death by 28%

- PMLiVE

GSK’s anaemia drug gets FDA advisory committee support for patients on dialysis

A final decision for daprodustat by the FDA is expected by 1 February 2023

AstraZeneca AZ

AstraZeneca’s Forxiga approved in Japan for the treatment of CKD

Approval was based on positive data from the phase 3 trial for chronic kidney disease

- PMLiVE

FDA requests further safety trials for AZ, FibroGen’s roxadustat

The response follows concerns over serious thrombotic events and seizures

Bayer symbol

Bayer’s finerenone scores FDA priority review for chronic kidney disease

FDA priority review is based on data from the phase 3 FIDELIO-DKD trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links